{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T18:43:19Z","timestamp":1792176199583,"version":"4.4.0"},"reference-count":60,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,12,12]],"date-time":"2022-12-12T00:00:00Z","timestamp":1670803200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Idiopathic inflammatory myopathies (IIMs) are a heterogeneous group of autoimmune diseases with various subtypes, myositis-specific antibodies, and affect multiple systems. The treatment of IIMs remains challenging, especially for refractory myositis. In addition to steroids and traditional immunosuppressants, rituximab (RTX), a B cell-depleting monoclonal antibody, is emerging as an alternative treatment for refractory myositis. However, the therapeutic response to RTX remains controversial. This meta-analysis aimed to systematically evaluate the efficacy and safety of RTX in patients with IIMs, excluding sporadic inclusion body myositis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>PubMed, Embase, Cochrane Library, China National Knowledge Infrastructure, and WanFang Data were searched for relevant studies. The overall effective rate, complete response rate, and partial response rate were calculated to assess the efficacy of RTX. The incidences of adverse events, infection, severe adverse events, severe infection, and infusion reactions were collected to evaluate the safety of RTX. Subgroup analyses were performed using IIM subtypes, affected organs, continents, and countries. We also performed a sensitivity analysis to identify the sources of heterogeneity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 26 studies were included in the quantitative analysis, which showed that 65% (95% confidence interval [CI]: 54%, 75%) of patients with IIMs responded to RTX, 45% (95% CI: 22%, 70%) of patients achieved a complete response, and 39% (95% CI: 26%, 53%) achieved a partial response. Subgroup analyses indicated that the overall efficacy rates in patients with refractory IIMs, dermatomyositis and polymyositis, as well as anti-synthetase syndrome were 62%, 68%, and 62%, respectively. The overall efficacy rates for muscle, lungs, and skin involvement were 59%, 65%, and 81%, respectively. In addition, studies conducted in Germany and the United States showed that patients with IIMs had an excellent response to RTX, with an effective rate of 90% and 77%, respectively. The incidence of severe adverse events and infections was 8% and 2%, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>RTX may be an effective and relatively safe treatment choice in patients with IIMs, especially for refractory cases. However, further verification <jats:italic>via<\/jats:italic> randomized controlled trials is warranted.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2022.1051609","type":"journal-article","created":{"date-parts":[[2022,12,12]],"date-time":"2022-12-12T05:58:43Z","timestamp":1670824723000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":63,"title":["Efficacy and safety of rituximab treatment in patients with idiopathic inflammatory myopathies: A systematic review and meta-analysis"],"prefix":"10.3389","volume":"13","author":[{"given":"Chao","family":"Zhen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaotian","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingjun","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanzhu","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,12,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/s41572-021-00321-x","article-title":"Idiopathic inflammatory myopathies","volume":"7","author":"Lundberg","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2019.07.006","article-title":"Idiopathic inflammatory myopathies","volume":"45","author":"Vencovsk\u00fd","year":"2019","journal-title":"Rheumatic Dis Clinics North America"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211468","article-title":"2017 European league against Rheumatism\/American college of rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"76","author":"Lundberg","year":"2017","journal-title":"Ann rheumatic Dis"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/art.21617","article-title":"Reconstitution of peripheral blood b cells after depletion with rituximab in patients with rheumatoid arthritis","volume":"54","author":"Leandro","year":"2006","journal-title":"Arthritis Rheumatism"},{"key":"B5","article-title":"Mechanisms of action of Cd20 antibodies","volume":"2","author":"Boross","year":"2012","journal-title":"Am J Cancer Res"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.144998","article-title":"Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis","volume":"70","author":"Buch","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216863","article-title":"Rituximab as therapy to induce remission after relapse in anca-associated vasculitis","volume":"79","author":"Smith","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"B8","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1136\/annrheumdis-2020-218272","article-title":"Update On the diagnosis and management of systemic lupus erythematosus","volume":"80","author":"Fanouriakis","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215089","article-title":"2019 update of the eular recommendations for the management of systemic lupus erythematosus","volume":"78","author":"Fanouriakis","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0706383","article-title":"B-cell depletion with rituximab in relapsing-remitting multiple sclerosis","volume":"358","author":"Hauser","year":"2008","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/ana.21867","article-title":"Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial","volume":"66","author":"Hawker","year":"2009","journal-title":"Ann Neurol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000003331","article-title":"Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy","volume":"87","author":"Salzer","year":"2016","journal-title":"Neurology"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01372","article-title":"Cd19cd24cd38 b cells are expanded in juvenile dermatomyositis and exhibit a pro-inflammatory phenotype after activation through toll-like receptor 7 and interferon-A","volume":"9","author":"Piper","year":"2018","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.091405","article-title":"Increased serum levels of b cell activating factor (Baff) in subsets of patients with idiopathic inflammatory myopathies","volume":"68","author":"Krystufkov\u00e1","year":"2009","journal-title":"Ann rheumatic Dis"},{"key":"B15","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.jneuroim.2012.04.006","article-title":"The expression of baff in the muscles of patients with dermatomyositis","volume":"249","author":"Baek","year":"2012","journal-title":"J neuroimmunology"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/art.37754","article-title":"Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: A randomized, placebo-phase trial","volume":"65","author":"Oddis","year":"2013","journal-title":"Arthritis rheumatism"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1097\/rhu.0000000000001620","article-title":"Rituximab for inflammatory myopathies in a Colombian cohort","volume":"27","author":"Santos","year":"2021","journal-title":"J Clin Rheumatol Pract Rep rheumatic musculoskeletal Dis"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0133702","article-title":"Efficacy of rituximab in refractory inflammatory myopathies associated with anti- synthetase auto-antibodies: An open-label, phase ii trial","volume":"10","author":"Allenbach","year":"2015","journal-title":"PloS One"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1056\/nejm197502132920706","article-title":"Polymyositis and dermatomyositis (First of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"New Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2004.02.006","article-title":"119th enmc international workshop: Trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, naarden, the Netherlands","volume":"14","author":"Hoogendijk","year":"2004","journal-title":"Neuromuscular Disord"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1046\/j.1445-2197.2003.02748.x","article-title":"Methodological index for non-randomized studies (Minors): Development and validation of a new instrument","volume":"73","author":"Slim","year":"2003","journal-title":"ANZ J Surg"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.150844","article-title":"Rituximab in the treatment of Jo1 antibody-associated antisynthetase syndrome: Anti-Ro52 positivity as a marker for severity and treatment response","volume":"43","author":"Bauhammer","year":"2016","journal-title":"J Rheumatol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s42358-018-0030-z","article-title":"Favorable rituximab response in patients with refractory idiopathic inflammatory myopathies","volume":"58","author":"de Souza","year":"2018","journal-title":"Adv Rheumatol (London England)"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kew396","article-title":"Cutaneous improvement in refractory adult and juvenile dermatomyositis after treatment with rituximab","volume":"56","author":"Aggarwal","year":"2017","journal-title":"Rheumatol (Oxford England)"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2020.35.e335","article-title":"Efficacy and safety of rituximab in Korean patients with refractory inflammatory myopathies","volume":"35","author":"Ahn","year":"2020","journal-title":"J Korean Med Sci"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kev004","article-title":"Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease","volume":"54","author":"Andersson","year":"2015","journal-title":"Rheumatol (Oxford England)"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.101321","article-title":"Safety and efficacy of rituximab in severe juvenile dermatomyositis: Results from 9 patients from the French autoimmunity and rituximab registry","volume":"38","author":"Bader-Meunier","year":"2011","journal-title":"J Rheumatol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-020-05013-7","article-title":"A prospective cross-sectional study of serum il-17a in antisynthetase syndrome","volume":"39","author":"Behrens Pinto","year":"2020","journal-title":"Clin Rheumatol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.143.6.763","article-title":"A pilot trial of rituximab in the treatment of patients with dermatomyositis","volume":"143","author":"Chung","year":"2007","journal-title":"Arch Dermatol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ker305","article-title":"Efficacy and safety of rituximab in the treatment of refractory inflammatory myopathies in adults: Results from the air registry","volume":"50","author":"Couderc","year":"2011","journal-title":"Rheumatol (Oxford England)"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-020-05530-5","article-title":"Anti-melanoma differentiation-associated gene 5 (Mda5) antibody-positive dermatomyositis responds to rituximab therapy","volume":"40","author":"Ge","year":"2021","journal-title":"Clin Rheumatol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.609595","article-title":"Antisynthetase syndrome-associated interstitial lung disease: Monitoring of immunosuppressive treatment effects by chest computed tomography","volume":"7","author":"Korsten","year":"2020","journal-title":"Front Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.171495","article-title":"Rituximab in the treatment of refractory anti-hmgcr immune-mediated necrotizing myopathy","volume":"46","author":"Landon-Cardinal","year":"2019","journal-title":"J Rheumatol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key450","article-title":"Efficacy and safety of rituximab in anti-synthetase antibody positive and negative subjects with idiopathic inflammatory myopathy: A registry-based study","volume":"58","author":"Leclair","year":"2019","journal-title":"Rheumatol (Oxford England)"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1002\/art.20849","article-title":"Rituximab in the treatment of dermatomyositis: An open-label pilot study","volume":"52","author":"Levine","year":"2005","journal-title":"Arthritis rheumatism"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ker088","article-title":"Rituximab treatment in patients with refractory inflammatory myopathies","author":"Mahler","year":"2011","journal-title":"Rheumatology"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2012.01.001","article-title":"Rituximab therapy for refractory interstitial lung disease related to antisynthetase syndrome","volume":"106","author":"Marie","year":"2012","journal-title":"Respir Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000000523","article-title":"In antisynthetase syndrome, acpa are associated with severe and erosive arthritis: An overlapping rheumatoid arthritis and antisynthetase syndrome","volume":"94","author":"Meyer","year":"2015","journal-title":"Medicine"},{"key":"B39","first-page":"896","article-title":"Rituximab as an effective alternative therapy in refractory idiopathic inflammatory myopathies","volume":"31","author":"Mu\u00f1oz-Beamud","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"B40","article-title":"Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases","volume":"28","author":"Ramos-Casals","year":"2010","journal-title":"Clin Exp Rheumatol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep157","article-title":"Rituximab treatment of the anti-synthetase syndrome: A retrospective case series","volume":"48","author":"Sem","year":"2009","journal-title":"Rheumatol (Oxford England)"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejr.2021.03.005","article-title":"Response to cyclophosphamide and rituximab therapy in idiopathic inflammatory myopathies: A single center experience","volume":"43","author":"Shahin","year":"2021","journal-title":"Egyptian Rheumatologist"},{"key":"B43","article-title":"Clinical outcome following b cell depletion therapy in eight patients with refractory idiopathic inflammatory myopathy","volume":"26","author":"Sultan","year":"2008","journal-title":"Clin Exp Rheumatol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu024","article-title":"Rituximab therapy in patients with refractory dermatomyositis or polymyositis: Differential effects in a real-life population","volume":"53","author":"Unger","year":"2014","journal-title":"Rheumatol (Oxford England)"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1080\/14728214.2020.1787985","article-title":"Clinical trials and novel therapeutics in dermatomyositis","volume":"25","author":"Chandra","year":"2020","journal-title":"Expert Opin emerging Drugs"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20212","article-title":"Mycophenolate mofetil for interstitial lung disease in dermatomyositis","volume":"62","author":"Morganroth","year":"2010","journal-title":"Arthritis Care Res"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1097\/MAJ.0b013e31818d094b","article-title":"Experience of mycophenolate mofetil in 10 patients with autoimmune-related interstitial lung disease demonstrates promising effects","volume":"337","author":"Saketkoo","year":"2009","journal-title":"Am J Med Sci"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)01927-3","article-title":"Tacrolimus in refractory polymyositis with interstitial lung disease","volume":"353","author":"Oddis","year":"1999","journal-title":"Lancet"},{"key":"B49","article-title":"Calcineurin inhibitors in a cohort of patients with antisynthetase-associated interstitial lung disease","volume":"31","author":"Labirua-Iturburu","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2117912","article-title":"Trial of intravenous immune globulin in dermatomyositis","volume":"387","author":"Aggarwal","year":"2022","journal-title":"N Engl J Med"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa459","article-title":"Intravenous immunoglobulins as first-line treatment in idiopathic inflammatory myopathies: A pilot study","volume":"60","author":"Lim","year":"2021","journal-title":"Rheumatol (Oxford)"},{"key":"B52","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.nmd.2017.09.016","article-title":"224th enmc international workshop:: Clinico-Sero-Pathological classification of immune-mediated necrotizing myopathies zandvoort, the Netherlands, 14-16 October 2016","volume":"28","author":"Allenbach","year":"2018","journal-title":"Neuromuscul Disord"},{"key":"B53","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1002\/ana.410160206","article-title":"Monoclonal antibody analysis of mononuclear cells in myopathies. I: Quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells","volume":"16","author":"Arahata","year":"1984","journal-title":"Ann Neurol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000187124.92826.20","article-title":"Plasma cells in muscle in inclusion body myositis and polymyositis","volume":"65","author":"Greenberg","year":"2005","journal-title":"Neurology"},{"key":"B55","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.autrev.2018.10.004","article-title":"Autoantibodies in idiopathic inflammatory myopathies: Clinical associations and laboratory evaluation by mono- and multispecific immunoassays","volume":"18","author":"Damoiseaux","year":"2019","journal-title":"Autoimmun Rev"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep078","article-title":"Myositis-specific autoantibodies: Their clinical and pathogenic significance in disease expression","volume":"48","author":"Gunawardena","year":"2009","journal-title":"Rheumatol (Oxford England)"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1136\/ard.60.2.116","article-title":"Autoantibody profiles in the sera of European patients with myositis","volume":"60","author":"Brouwer","year":"2001","journal-title":"Ann rheumatic Dis"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1007\/s12026-013-8408-9","article-title":"Rituximab in refractory idiopathic inflammatory myopathies and antisynthetase syndrome: Personal experience and review of the literature","volume":"56","author":"Nalotto","year":"2013","journal-title":"Immunol Res"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1002\/art.38270","article-title":"Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis","volume":"66","author":"Aggarwal","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kev444","article-title":"Autoantibody levels in myositis patients correlate with clinical response during b cell depletion with rituximab","volume":"55","author":"Aggarwal","year":"2016","journal-title":"Rheumatol (Oxford)"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1051609\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,12]],"date-time":"2022-12-12T05:58:47Z","timestamp":1670824727000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1051609\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,12]]},"references-count":60,"alternative-id":["10.3389\/fimmu.2022.1051609"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.1051609","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,12]]},"article-number":"1051609"}}